Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Johnson & Johnson (JNJ): Why The Walt Disney Company (DIS) Buys All the Premium Character Collections It Can Find

Every so often, The Walt Disney Company (NYSE:DIS) faces an uncomfortable dilemma. The copyright on Disney’s most prized character, Mickey Mouse, won’t last forever, and the expiration date is drawing close again. The Mouse is slated to enter the public domain in 2018.

That’s why The Walt Disney Company (NYSE:DIS) spent $4.1 billion on Star Wars studio Lucasfilm last year. It’s also a big reason behind the $4 billion Marvel deal in 2009. Mickey’s copyright woes may even have played a part in the crucial 2006 buyout of Pixar for $7.6 billion.

Mickey Mouse doesn’t exactly jump out and greet you at this Disney store. It’s a sign of the times.

The Walt Disney Company (NYSE:DIS) CEO Bob Iger is busy constructing a framework of top-shelf characters to replace Mickey’s iconic profile at the heart of the company. Buzz Lightyear can’t do it alone, nor can Spider-Man or Wolverine. Even Luke Skywalker is a stretch.

So The Walt Disney Company (NYSE:DIS) is diversifying into a number of clearly defined niches. Each one comes with a central cast of characters that can carry The Walt Disney Company (NYSE:DIS)’s branding flag when Mickey steps aside. In-house princesses from Snow White to Merida cater to a mostly young, female audience. Marvel’s superheroes and villains do the heavy lifting for older boys, with Darth Vader and Yoda coming up behind them. The Pixar stable has something for everyone.

I don’t know if you’ve noticed, but Mickey’s stature is already shrinking. Disney hasn’t even made a direct-to-video feature starring him since 2004. These days, the Mouse only stars in video games and The Walt Disney Company (NYSE:DIS) Channel TV shows. And it’s for good reason. When Mickey’s copyright expires in 2018 — just five short years away — the market may (and probably will) be flooded with knock-offs. Disney also holds a fiercely protected trademark on Mickey, so nobody can pull off a complete rip-off job, but the iconic mouse ears and the rest of the design will become fair game. Compare this to how anybody can make and sell adhesive bandages, but only Johnson & Johnson (NYSE:JNJ) can use the Band-Aid brand.

Barring another miraculous fourth-quarter save, which doesn’t seem likely this time, Disney needs to adjust to this upcoming legal reality. Mickey copies will be everywhere under a variety of new names, diluting the character’s value.

But Disney plans to remain relevant and profitable, with or without Mickey Mouse in the spotlight. Disney became a Dow member in 1992, purely on the strength of its homebrew (and old public-domain) characters. The stock largely kept pace with its Dow peers in the early years of index membership, but it has absolutely crushed the Dow recently.

DIS Chart

DIS data by YCharts.

That’s Mickey’s scheduled replacements flexing their muscles. I think they’ll be more than ready when the baton is passed in 2018.

The article Why Disney Buys All the Premium Character Collections It Can Find originally appeared on and is written by Anders Bylund.

Fool contributor Anders Bylund holds no position in any company mentioned. Check out Anders’ bio and holdings or follow him on Twitter and Google+. The Motley Fool owns shares of Walt Disney. Motley Fool newsletter services have recommended buying shares of Johnson & Johnson and Walt Disney. Motley Fool newsletter services have recommended buying calls on Johnson & Johnson. 

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!